Clinical trial · no report yet · Phase 2/Phase 3
NCT02919787
Nordic Pancreatic Cancer Trial (NorPACT) - 1
- NCT02919787 ↗
- Active not recruiting
- Oslo University Hospital
- 22 commentary sources found
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 19 | |
| Podcasts | 2 | |
| YouTube | 1 |
The trial
ClinicalTrials.gov- Official title
- Nordic Multicentre Un-blinded Phase II Randomized Controlled Trial (RCT) Evaluating the Additional Efficacy of Adding Chemotherapy Prior to Resection of a Pancreatic Head Malignancy to Avoid Early Mortality in Those Ultimately Resected
- Phase
- Phase 2/Phase 3
- Status
- Active not recruiting
- Conditions
- Pancreatic Cancer
- Interventions
- 5-FU; Oxaliplatine; Irinotecan; Pancreatic surgery; 5-FU; Oxaliplatine; Irinotecan
- Arms
- Surgery and then postoperative adjuvant chemotherapy · Active comparator
- Neoadjuvant chemotherapy, surgery, adjuvant chemotherapy · Experimental
- Enrollment
- 140 (estimated)
- Primary outcomes
- Overall survival 18 month after randomization
- Sponsor
- Oslo University Hospital with St. Olavs Hospital, Haukeland University Hospital, University Hospital of North Norway, Sahlgrenska University Hospital, Karolinska University Hospital, University Hospital, Linkoeping, Lund University Hospital, Odense University Hospital, Helsinki University Hospital, Finland, Norrlands University Hospital, Helse Stavanger HF
- Start
- Sep 2016
- Primary completion
- Dec 22, 2022
- Results posted
- No
- Registry record
- NCT02919787 · updated Nov 20, 2024
Publications
linked from the registry- Labori KJ, Bratlie SO, Andersson B, Angelsen JH, Biorserud C, Bjornsson B, Bringeland EA, Elander N, Garresori H, Gronbech JE, Haux J, Hemmingsson O, Liljefors MG, Myklebust TA, Nymo LS, Peltola K, Pfeiffer P, Sallinen V, Sandstrom P, Sparrelid E, Stenvold H, Soreide K, Tingstedt B, Verbeke C, Ohlund D, Klint L, Dueland S, Lassen K; Nordic Pancreatic Cancer Trial-1 study group. Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): a multicentre, randomised, phase 2 trial. Lancet Gastroenterol Hepatol. 2024 Mar;9(3):205-217. doi: 10.1016/S2468-1253(23)00405-3. Epub 2024 Jan 15. PubMed 38237621
- Labori KJ, Lassen K, Hoem D, Gronbech JE, Soreide JA, Mortensen K, Smaaland R, Sorbye H, Verbeke C, Dueland S. Neoadjuvant chemotherapy versus surgery first for resectable pancreatic cancer (Norwegian Pancreatic Cancer Trial - 1 (NorPACT-1)) - study protocol for a national multicentre randomized controlled trial. BMC Surg. 2017 Aug 25;17(1):94. doi: 10.1186/s12893-017-0291-1. PubMed 28841916